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Abstract
Objectives To evaluate the short- and medium-term results
of prostatic arterial embolisation (PAE) for benign prostatic
hyperplasia (BPH).
Methods This was a prospective non-randomised study includ-
ing 255 patients diagnosed with BPH and moderate to severe
lower urinary tract symptoms after failure of medical treatment
for at least 6 months. The patients underwent PAE between
March 2009 and April 2012. Technical success is when selec-
tive prostatic arterial embolisation is completed in at least one
pelvic side. Clinical success was defined as improving symp-
toms and quality of life. Evaluation was performed before PAE
and at 1, 3, 6 and every 6 months thereafter with the Interna-
tional Prostate Symptom Score (IPSS), quality of life (QoL),
International Index of Erectile Function (IIEF), uroflowmetry,
prostatic specific antigen (PSA) and volume. Non-spherical
polyvinyl alcohol particles were used.
Results PAE was technically successful in 250 patients
(97.9 %). Mean follow-up, in 238 patients, was 10 months
(range 1–36). Cumulative rates of clinical success were
81.9 %, 80.7 %, 77.9 %, 75.2 %, 72.0 %, 72.0 %, 72.0 %
and 72.0 % at 1, 3, 6, 12, 18, 24, 30 and 36 months,
respectively. There was one major complication.
Conclusions PAE is a procedure with good results for BPH
patients with moderate to severe LUTS after failure of
medical therapy.
Key Points
• Prostatic artery embolisation offers minimally invasive
therapy for benign prostatic hyperplasia.
• Prostatic artery embolisation is a challenging procedure
because of vascular anatomical variations.
• PAE is a promising new technique that has shown good
results.
Keywords Benign prostatic hyperplasia . Therapeutic
embolization . Prostatic diseases . Angiography .
Catheterization
Abbreviations
BPH benign prostatic hyperplasia
PAE prostatic artery embolisation
Introduction
Benign prostatic hyperplasia (BPH) has a prevalence of over
50 % in men over 60 years [1]. It is associated with lower
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urinary tract symptoms (LUTS) such as higher urinary fre-
quency, urgency, leaking, hesitancy, interrupted and/or de-
creased urinary stream, and in some patients sexual
dysfunction, which may also be caused by medical therapy
(ejaculation disorders and impotence) [2, 3]. The indication
for treatment depends on the severity and bother of urinary
symptoms. LUTS severity is evaluated by the International
Prostate Symptom Score (IPSS): mild LUTS (IPSS 1–7),
moderate LUTS (8–19) and severe LUTS (20–35).
Medical therapy is usually the first-line treatment option
and is indicated for patients with moderate lower urinary
symptoms (patients with IPSS between 8 and 19) [4–6].
Medical therapies for BPH relief include alpha-blockers
and 5-alpha-reductase inhibitors (5-ARI). Medical therapy
is indicated for patients with moderate lower urinary symp-
toms with no absolute surgical indications [6, 7].
Minimally invasive treatments, including interstitial laser
ablation, transurethral microwave treatment and transure-
thral needle ablation, were originally conceived as an at-
tempt to offer equivalent efficacy as operative therapy but
without the burden and risk of operative morbidity [8].
Surgery is usually performed to improve symptoms and
decrease progression of disease in patients who develop
complications or who have inadequately controlled symp-
toms while taking medical treatment.
Prostatectomy may be performed through the urethra (i.e.
transurethral resection of the prostate, TURP) if the prostate
is smaller than 60–80 cm3, or by open surgery if the prostate
is larger. Both are associated with a significant complication
rate. None of the minimally invasive treatments has proven
superior to TURP from a cost/benefit standpoint, and TURP
remains the standard effective treatment [9, 10].
TURP is the most common surgical treatment for severe
symptomatic BPH patients in whom medical therapy has
failed. Although spinal anaesthesia is the most frequently
used for TURP all patients should be suitable for general
anaesthesia. Blood loss should be considered a frequent
complication.
Although both medical and surgical treatment options for
BPH are effective, they are associated with significant mor-
bidity rates and some degree of sexual dysfunction. There-
fore, there is the need for innovative technologies to
continue to improve outcomes and minimise patient discom-
fort and morbidity when managing BPH.
Prostatic arterial embolisation (PAE) for BPH has been
shown to be safe and effective at inducing prostatic volume
reduction in animals and humans [11–15]. Mauro [16]
reported that BPH might be the next step after uterine artery
embolisation (UAE) for fibroids.
Although the studies so far have been on few patients,
short-term studies of BPH have shown that PAE is a safe
and effective procedure, improves LUTS related to BPH and
is associated with a decrease in prostate volume [14, 15].
The purpose of this study was to retrospectively evaluate
the short- and medium-term results of PAE in 251 patients
with BPH with moderate to severe LUTS and failure of
medical therapy for at least 6 months.
Materials and methods
From March 2009 to April 2012, 255 patients aged 45–
85 years (mean 65.5±7.4 years) who presented with a diag-
nosis of BPH with moderate to severe LUTS refractory to
medical treatment for at least 6 months were selected for PAE.
This prospective study was approved by the hospital ethics
committee and an informed consent form for PAE as an
alternative treatment was signed by all participants. Efficacy
variables of IPSS, quality of life-related symptoms (QoL),
International Index of Erectile Function (IIEF), uroflowmetry
(Qmax, peak urinary flow; PVR, post-void residual volume),
prostatic specific antigen (PSA) and prostatic volume were
assessed before PAE and at 1, 3, 6 and every 6months after the
procedure. The prostate volume was assessed by transrectal
ultrasound (TRUS) and also measured by magnetic resonance
(MR) before PAE and 6 months after PAE in the first 15
patients. The baseline data were obtained from the evaluation
of these parameters (Table 1). The inclusion criteria were male
patients with age over 45 years and a diagnosis of BPH with
moderate to severe LUTS (IPSS >18) and/or QoL at least 3,
refractory to medical treatment for at least 6 months, and/or
with Qmax inferior to 12 mL/s or with acute urinary retention
and prostate larger than 40 cm3 with sexual dysfunction or
accepting the risk of developing sexual dysfunction after
treatment.
Prostatic biopsy was performed in all cases of suspected
prostatic malignancy due to a PSA level greater than 4 ng/mL
or due to suspicious focal lesions detected on TRUS or MRI.
Exclusion criteria were malignancy, advanced atheroscle-
rosis and tortuosity of the iliac arteries, secondary renal
insufficiency (due to prostatic obstruction), large bladder
diverticula or stones, neurogenic bladder and detrusor
failure.




IPSS 24.1 6.57 4–35
QoL 4.39 0.95 2–6
IIEF 18.9 8.73 0–34
Qmax (mL/s) 9.19 4.47 1.5–26.8
Prostate volume (cm3) 83.5 37.0 24–269
Post-void residual volume (mL) 102.9 88.9 0–445
PSA (ng/mL) 5.68 6.76 0.14–58.7
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All patients were informed about the embolisation and
other therapeutic options for their clinical situation including
TURP, open surgery and laser treatment. The patients were
allowed to choose freely between PAE, TURP/open surgery
or minimally invasive treatment including laser surgery.
All the parameters mentioned above were evaluated in
238 patients at 1 month, 192 at 3 months 144 at 6 months,
89 at 12 months, 47 at 18 months, 21 at 24 months, 12 at
30 months and 8 at 36 months.
All patients were on medical therapy for BPH with per-
sisting moderate to severe symptoms for more than
6 months. Eight patients had TURP years before and 32
patients had bladder catheters at the time, owing to acute
urinary retention.
Pelvic magnetic resonance angiography (MRA) using a
1.5-T system (Philips, Eindhoven, the Netherlands) was
performed before PAE to evaluate the pelvic vessels for tor-
tuosity and atherosclerotic changes of the iliac arteries in the
first 15 patients. In the remaining patients pelvic CT angiog-
raphy (CTA) was performed using a 16-row GE (R) Scanner
(Fairfield, CT, USA). A specific CTangiography protocol was
applied and post-processing using maximum intensity projec-
tions (MIP) and volume rendering with 3D reconstructions
were obtained [17, 18]. The anatomy and the atherosclerotic
involvement of the prostatic arteries could thereby be known
in advance, before the procedure (Fig. 1). We can also assess
the degree of calcium and stenosis of prostatic origin, which
also plays an important role in excluding some of the patients.
CTA also reduces radiation during the procedure (digital
subtraction angiography (DSA), or cone-beam CT eventually
needed), the procedure time and contrast agent injection. It
helps the team, giving them confidence, so that they do not get
Fig. 1 Computed tomography
angiography (CTA) and digital
subtraction angiography (DSA)
of internal iliac arteries (IIA) to
show the origin of prostatic ar-
teries. a–c Right IIA. a Volume
rendering with CT reconstruction
of right IIA: right prostatic artery
(open arrow) originates from the
obturator (arrow). bMaximum
intensity project (MIP) of the
right IIA: prostatic artery (open
arrow) originates from the obtu-
rator artery (arrow). c DSA of
the anterior trunk of the right IIA
after selective catheterisation:
confirms the origin of the pros-
tatic (open arrow) artery from
the obturator (arrow). d–f Left
IIA. d Volume rendering with
CT reconstruction of left IIA: left
prostatic artery (open arrow)
originates from the obturator
(arrow). eMIP of left IIA: pros-
tatic artery (open arrow) origi-
nates from the obturator artery
(arrow). f DSA of the anterior
trunk of the left IIA after selec-
tive catheterisation: confirms or-
igin of the prostatic (open arrow)
artery from the obturator (arrow)
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lost with the anatomy during the procedure. It avoids catheter-
isation of all other pelvic arteries and ultimately will reduce
complications.
Embolisation technique
Patients started an acid-suppressing drug (omeprazole
20 mg, Bluepharma, once daily), an anti-inflammatory (nap-
roxen 1,000 mg, naprosyn, Roche, twice daily) and an
antibiotic (ciprofloxacin, 750 mg Jaba, twice daily) 2 days
before the procedure and continued for 7 days following
PAE. On the day of PAE, the patients had the same medi-
cation at breakfast and at dinner 8 h after PAE. The patients
were admitted to the hospital on the day of the procedure,
2 h before the intervention. During embolisation an anti-
allergic (hydroxyzine 25 mg, Atarax) was given orally, an
analgesic (metamizole 2 g i.v., Nolotil, Boehringer Ingel-
heim) and an anti-inflammatory (ketorolac tromethamine
30 mg i.v., Toradol, Roche) were given intravenously.
The embolisation was planned in advance, on the bases
of CT, particularly the volume rendering with CT recon-
structions and the MIP. These examination results were
available in the angiography suite at the time of the proce-
dure (Fig. 1).
Embolisation was performed under local anaesthesia us-
ing a unilateral approach, mostly via the right femoral artery.
For this purpose a 5-F RUC (Roberts Uterine Catheter,
Cook Medical, Bloomington, USA) catheter or a cobra-
shaped C2 catheter (Cook Medical, Bloomington, USA)
was introduced into the right femoral artery in order to
catheterise the left internal iliac artery (IIA) and its anterior
division. With the catheter at the initial segment of the IIA,
DSA was obtained in the ipsilateral oblique view 35° and
10° cranio-caudal with 6 mL of iodine contract medium
(Iopamiro 300, Iomeron, Bracco, Italy) at 3 mL/s, to visu-
alise the prostatic arteries (Fig. 2a). After identifying the left
prostatic arteries, we obtained a road map with the catheter
at the origin of the artery in which those arteries originate
(Fig. 2b). Afterwards the prostatic vessels were selectively
catheterised with a coaxial microcatheter (Progreat 2.7 or
Progreat 2.4 with a GT microwire; Terumo, Tokyo, Japan)
or 2.5 Cantata and Sagitta (Cook Medical) (Fig. 2c). Anoth-
er angiogram was performed to confirm the position of the
catheter in the ostium of the prostatic artery, and the
prostate vascularisation in the same left anterior oblique
(Fig. 2d). The microcatheter was then advanced distally
into the prostatic artery before embolisation and an
angiogram was obtained. Following that, another angio-
gram of the prostatic artery in neutral projection was
performed, in order to confirm that the catheter was in
the prostatic artery by overlying it with the pubic bone
(Figs. 3 and 4).
Upon finishing the embolisation of the left prostatic
arteries, we removed the microcatheter and the Waltman
loop was formed on the C2 or RCU and the right prostatic
arteries were embolised in the same manner. After confirm-
ing the position of the catheter in the ostium of the prostatic
artery, we placed the microcatheter distally in the artery and
the embolisation was carried out.
For embolisation 200-μm non-spherical polyvinyl alco-
hol (PVA) particles were used (Cook Medical, USA) in the
first 14 patients and 100 μm or 200 μm in the remaining
Fig. 2 Catheterisation of
prostatic artery. a Digital
subtraction angiography (DSA)
of the left internal iliac artery
(IIA). b Road map of the left
pudenda artery (arrow) from
which the prostatic artery (open
arrow) originates. c Micro-
guidewire (open arrow) placed
in the prostatic artery. d Selec-
tive angiogram of the prostatic
artery through micro-catheter
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patients. One millilitre of PVA particles was diluted in a
solution of 50 mL saline and contrast medium in a 1:1
proportion and mixed with ketoprofene (50 mg) and cefa-
zoline (100 mg). The particles were slowly injected
through a 3-mL syringe under fluoroscopic control until
we reached the end point. The end point of embolisation
chosen was “near stasis” in the prostatic vessels with
interruption of the arterial flow and prostatic gland opaci-
fication (Fig. 5).
Pain assessment was performed during and in the 6–8 h
following PAE by visual analogue scale (VAS). Patients
were asked to rate their pain severity from 0 (sensation of
no pain) to 10 (the worst pain).
Technical success was considered when selective prostat-
ic arterial catheterisation and embolisation was achieved at
least on one side of the pelvis.
IPSS, QoL, Qmax, IIEF, PVR, PSA and prostate volume
were evaluated at 1, 3, 6 and every 6 months after the proce-
dure. The prostate volume changeswere evaluated byTRUS in
all patients and in some patients also byMRI. All patients filled
in the questionnaires by themselves without any exterior help
(i.e. they were self-filled by the patients as recommended).
Clinical success was defined as improving symptoms
(IPSS reduction at least 25 % of the total score and lower than
18 points) after PAE and improving of quality of life (reduc-
tion of QoL of at least 1 point or equal to or below 3 points).
Statistical analysis
Response variables (IPSS, QoL, Qmax, PVR, PSA, prostate
volume and IIEF) were analysed with random effects gen-
eralized least-squares (GLS) regression with an AR (1) error
structure. Prostate volume, Qmax and PSAwere logarithmi-
cally transformed to obtain a normal distribution. Observa-
tion time was entered into the model as a categorical
variable. No adjustment for multiplicity was done. Rates
of clinical improvement over time were analysed using the
Kaplan–Meier method to account for incomplete follow-up
times. The Stata software release 12 (Stata Corp., College
Station, TX, USA) was used for all analyses. Statistical
differences were assumed at P<0.05.
Results
Prostatic artery embolisation was technically successful in
250 of the 255 (98 %) selected patients. In 5 patients (2 %)
the procedure was impossible owing to tortuosity and ath-
erosclerotic changes of the iliac arteries; surgery was per-
formed in these cases. PAE was bilateral in 205 patients
(82 %) and unilateral in 45 patients (18 %) also owing to the
tortuosity and atherosclerotic changes of the iliac arteries.
The procedure time was between 20 and 185 min (mean
73 min) and the fluoroscopy time ranged between 7 and
64 min (mean 18 min). Mean follow-up time was 10 months
(range 1–36 months).
The degree of pain ranged from 0 to 10 (mean 1.7);
however 191/250 (76.4 %) patients did not feel any pain.
Only one patient felt very severe pain (degree 9) during
embolisation; the patient later developed a small area of
bladder wall ischaemia.
Two hundred and twenty patients (88 %) were discharged
from the hospital 3–8 h after the procedure and the remain-
ing 30 patients (12 %) 18 h after, the next morning.
Fig. 3 Digital subtraction angiography (DSA) of the right prostatic
artery, oblique and neutral views. Prostate bed pacification. a DSA of
the right prostatic artery, oblique view. b DSA of the right prostatic
artery, AP view. c Prostate bed opacification of the right lobe (arrow),
overlying the pubic bone
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Follow-up data were available for 242 patients, who were
observed for a mean of 10 months (range 1–36 months).
Eight patients were lost to follow-up and 4 did not provide
efficiency data. Efficacy data were available for 238
patients. Of these 238 patients, there was short-term clinical
success at 1 month in 195 (81.9 %) and 43 (18.1 %) had
clinical failures. Twenty four hours after PAE 102 patients
(42.85 %) had already improved. All clinical failures had
severe symptoms after PAE (IPSS persisted above 18 and
QoL≥4). Clinical failure had no direct relationship with
prostate volume reduction. Fifty-two of the 56 failures had
complete follow-up data on prostate volume. In 23 of them
there was no clinical success in spite of the significant
(>15 %) prostate volume reduction. In the remaining 29
patients the prostate volume decreased less than 15 % in
16 and increased in 13 patients. On the other hand 12
patients had clinical success in spite of significant increase
of prostate volume.
In 12 of the failures only unilateral embolisation could be
performed and in 6 the embolisation was incomplete owing to
advanced atherosclerosis that was not shown on CT angiog-
raphy. In the remaining 25 patients with clinical failure the
embolisation performed was bilateral and complete. PAE was
successfully repeated and performed in the non-embolised
prostatic artery in 4 of the 12 patients with unilateral emboli-
sation. The procedure was repeated through another femoral
approach, 2 weeks afterwards with clinical success.
Kaplan–Meier estimates of the cumulative rate of clinical
success at other follow-up times were as follows: 80.7 %
(95 % confidence interval (CI) 75–85.1 %) at 3 months,
77.9 % (95 % CI 71.9–82.7 %) at 6 months, 75.2 % (95 %
CI 68.6–80.6 %) at 12 months, 72.0 % (95 % CI 64.1–
Fig. 4 Embolisation of the
prostatic arteries, oblique and
AP view. Digital subtraction
angiography (DSA) of the right
prostatic artery (PA) (a–c).
Oblique view before embolisa-
tion (a); AP view before embo-
lisation (b); after embolisation
(c). DSA of the left PA (d–f):
oblique view before embolisa-
tion (d); AP view before
embolisation (e); DSA after
embolisation (f)
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78.5 %) at 18 months, 72.0 % (95 % CI 64.1–78.5 %) at
24 months, 72.0 % (95 % CI 64.1–78.5 %) at 30 months and
72.0 % (95 % CI 64.1–78.5 %) at 36 months (Table 2).
A statistically significant improvement over time of all
evaluated parameters was observed (Table 3 and Figs. 6 and 7).
Thirty-two patients were on urinary retention with blad-
der drainage catheter. The bladder catheters were removed
between 5 and 60 days after the procedure in 30 of the
patients who started to urinate successfully.
Ultrasound and MRI performed after PAE showed pros-
tate volume changes and MRI showed ischaemia zones of
the prostate (Figs. 8, 9).
Six of the 56 patients who were followed up to 18 months
had failure with acute urinary retention and a bladder cath-
eter was placed. Four of the patients improved after repeated
PAE and the bladder catheter was removed. The remaining 2
patients had an open prostatectomy because of advanced
atherosclerosis.
We considered IIEF improvement as any rise of IIEF
score. In 199 patients with follow-up data on IIEF, the score
Fig. 5 Prostatic arteries
embolisation. a Digital
subtraction angiography (DSA)
of the anterior division of right
internal iliac artery (IIA). b
DSA right prostatic artery (PA),
before embolisation. c DSA
right PA, after embolisation,
fewer branches are shown. d
DSA of the anterior division the
left IIA. e DSA left PA, before
embolisation. f DSA PA, after
embolisation, fewer vessels are
shown









1 238 43 81.9 76.4 86.3
3 192 3 80.7 75.0 85.1
6 144 5 77.9 71.9 82.7
12 89 3 75.2 68.6 80.6
18 47 2 72.0 64.1 78.5
24 21 0 72.0 64.1 78.5
30 12 0 72.0 64.1 78.5
36 8 0 72.0 64.1 78.5
Eur Radiol
improved in 96 (48.2 %), remained stable in 43 (21.6 %)
and had no significant worsening in 60 (30.2 %). There were
no cases of sexual impotence or retrograde ejaculation after
PAE.
There was only one major complication: a bladder is-
chaemia. A bladder mass was removed from that patient by
simple surgery 1 month later and was confirmed by pathol-
ogy to be necrosis and desquamation of the bladder wall.
The patient suffered no further sequelae.
As an adverse event, 23/250 (9.2 %) patients experienced
a burning sensation in the urethra and/or in the anus during
the procedure. Nineteen of the 250 patients with urinary tract
infections after embolisation (7.6 %) were treated with anti-
biotics. Fourteen of the 19 patients with urinary tract infec-
tion already had a urinary infection at the time of
embolisation as proven by urine culture before the proce-
dure. Transient haematuria occurred in 14/251 (5.6 %)
patients, transient haematospermia in 10/250 (0.4 %), a small
rectorrhagia in 6/250 (2.4 %) and balanitis in 4 (1.6 %)
patients. All these minor complications disappeared sponta-
neously without any treatment. Six patients had transient
acute urinary retention after PAE. For relief, a temporary
bladder catheter was placed at the time for a couple of hours.
Discussion
This prospective study shows that PAE performed in patients
with BPH and moderate to severe LUTS refractory to medical
therapy is a clinically successful procedure and may be an
alternative to surgery. We thus present prostatic embolisation
as an alternative to surgery. Therefore we accepted the same
indications for PAE as those for surgery. In fact urinary
retention and borderline urinary symptoms despite medical
therapy were the main indications for patients selected for this
trial. The European Association of Urology (EAU) guidelines
Table 3 Mean values over time of response variables
Variable Month No. pts. Mean 95 % confidence
interval
Pa
IPSS 0 238 24.0 23.3 24.9 <0.0001
1 236 12.2 11.4 13.1
3 224 11.0 10.2 11.8
6 167 11.5 10.4 12.5
12 101 10.4 9.1 11.7
18 58 10.1 8.4 11.9
24 25 9.0 6.4 11.6
30 14 8.1 4.8 11.5
36 9 9.1 4.1 14.1
QoL 0 238 4.40 4.28 4.52 <0.0001
1 236 2.48 2.32 2.64
3 221 2.23 2.08 2.38
6 167 2.27 2.08 2.47
12 102 1.96 1.72 2.20
18 54 1.83 1.50 2.16
24 25 1.76 1.36 2.16
30 13 1.85 1.43 2.26
36 9 1.67 1.12 2.21
Qmax (mL/s) 0 208 9.2 8.6 9.8 <0.0001
1 185 11.9 11.0 12.8
3 146 12.4 11.3 13.4
6 105 12.0 11.0 13.1
12 60 12.8 11.4 14.1
18 25 13.0 9.4 16.5
24 12 13.9 9.9 18.0
30 2 10.8 −75.6 97.2
PVR (mL) 0 210 102.9 90.8 114.9 <0.0001
1 175 65.6 54.1 77.0
3 134 59.2 49.4 69.1
6 99 62.8 50.0 75.5
12 58 51.7 37.1 66.4
18 23 75.4 46.5 104.3
24 13 91.9 24.2 159.6
30 3 95.3 −86.9 277.6
PV (mL) 0 238 83.5 78.8 88.2 <0.0001
1 183 66.8 62.6 71.0
3 147 68.3 63.2 73.3
6 111 66.6 60.8 72.4
12 63 69.9 61.8 78.0
18 29 72.0 57.5 86.5
24 14 90.9 62.6 119.1
30 4 72.0 13.7 130.3
PSA (ng/mL) 0 238 5.68 4.81 6.54 <0.0001
1 195 4.23 3.55 4.91
3 150 3.64 3.06 4.22
6 111 4.30 3.49 5.11
12 62 5.08 3.77 6.39
18 28 6.08 3.57 8.59
24 13 6.10 3.33 8.87
Table 3 (continued)
Variable Month No. pts. Mean 95% confidence
interval
Pa
30 3 7.41 −3.91 18.7
IIEF 0 230 18.9 17.7 20.0 0.0002
1 197 20.6 19.5 21.7
3 152 20.9 19.7 22.1
6 110 20.5 18.2 21.9
12 65 20.1 18.2 22.0
18 25 20.4 17.1 23.6
24 12 18.7 12.2 25.2
30 3 20.0 −6.17 46.2
a Random effects GLS regression. A significant P value is evidence
that the mean value of an outcome variable changes over time
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consider that although uroflowmetry does not allow one to
make the diagnosis of obstruction, pressure flow studies are
indicated before surgery only when Qmax is over 15 mL/s.
Anyway we decided to be more strict and included patients
with borderline urinary symptoms but with a Qmax lower than
12. For that reason we followed strictly the inclusion and
exclusion criteria: IPSS should be more than 18, or the QoL
at least 4, the Qmax under 12 mL/s or in acute urinary
retention, the prostate volume larger than 40 cm3 and the
patients should have been under refractory medical treatment
for at least 6 months.
Most clinical changes occur in the first month after PAE.
The clinical improvement is fast and 102 patients had im-
proved in 24 h and another 93 had improved by 1 month
after the procedure. Therefore, at 1 month 195 had clinical
improvement and 43 had clinical failure. Forty-three of the
56 clinical failures (76.8 %) occurred in the first month.
Among those with clinical improvement by 3 months, only
20 (11 %) had not improved by 1 month. A retrospective
review of the angiographic findings of the procedure in
patients with clinical failures showed that in 12 patients
the embolisation was unilateral and in 6 it was incom-
plete. However in the remaining 25/238 patients
(10.5 %) both prostatic arteries were embolised. There-
fore, to the best of our knowledge, there was no tech-
nical reason for the clinical failure. Because of this, the
patients should be informed of the unpredictable results
of PAE, even with complete embolisation of both pros-
tatic arteries with a possible clinical failure rate of up to
25 % at 3 years.
Pre-procedural CT angiography is very important for
evaluating the atherosclerotic changes of the iliac and pros-
tatic arteries and the possible anastomoses of prostatic ar-
teries either to vesical or to rectal arteries, in order to avoid
non-target embolisation. On the basis of CT angiography the
patients have to be excluded if they have severe atheroscle-
rotic changes or if the anatomy is not suitable. However, the
CT angiograph may not show small plaques as occurred in 6
patients with incomplete embolisation, a finding that was
not predictable before the procedure. There are no specific
MR protocols to evaluate prostatic artery anatomy with
the same information that CTA gives us. Alternatively,
Fig. 6 Change from baseline
over time after PAE of IPSS,
QoL, PVR and IIEF. Point
estimates and 95 % confidence
intervals. PAE prostatic artery
embolisation, IPSS
International Prostate
Symptoms Score, QoL quality
of life, IIEF International Index
of Erectile Function
Fig. 7 Percentage change from
baseline over time after PAE of
Qmax and prostate volume.
Point estimates and 95 %
confidence intervals. PAE
prostatic artery embolisation,
Qmax peak urinary flow, PV
prostate volume
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complementary cone-beam CT should be used in doubt-
ful cases [19].
There was not a relationship between the reduction in
prostatic volume and the clinical outcome (P00.12).
Twenty-three of our patients with clinical failure had signifi-
cant (>15 %) prostate volume reduction and 12 patients had
clinical success in spite of a significant increase in prostate
volume. Therefore the clinical success cannot be predicted on
the basis of prostate volume reduction. Patients with the same
prostate volume change may have different clinical outcomes.
PAE is a safe and painless outpatient procedure with low
morbidity in most cases. There was only one major compli-
cation—bladder wall ischaemia—that occurred early in our
experience (patient 10). It manifested as an intraluminal
volume of necrotic tissue that was removed by simple sur-
gery without need for bladder reconstruction. To prevent
complications a good knowledge of the prostatic anatomy
is important in order to perform a superselective catheter-
isation of prostatic arteries avoiding untargeted embolisation
of other arteries such as the vesical, rectal and dorsal artery
of the penis [17, 18].
PAE is usually a painless procedure; all patients were
treated as outpatients and 220 patients (88 %) were dis-
charged 3–8 h after the procedure.
Fig. 8 Trans-rectal ultrasound. Prostate volume reduction after PAE. a, b Prostate volume before PAE (18 June 2009), 121 cm3. c, d Prostate
volume after PAE (20 August 2009), 93.5 cm3 (i.e. 22.9 % reduction)
Fig. 9 MRI of the prostate
before and after PAE. a MRI
before PAE. b MRI 18 days
after PAE. Lower intensity ones
in both prostate lobes due to
ischaemia
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There were no cases of sexual dysfunction including
impotence or retrograde ejaculation. The sexual function
improved in 96 (48.2 %) of the patients and had no signif-
icant differences in the remaining patients. The improve-
ment in sexual function might be explained by the
withdrawal of the prostatic medication that affects it and
by the improvement in urinary symptoms and quality of life.
The PAE compares favourably with surgery where retro-
grade ejaculation occurs very frequently.
The main advantages of PAE are preservation of the
sexual function with no cases of impotence or retrograde
ejaculation, the minimally invasive nature of the procedure,
the low morbidity, the possibility of stopping the daily BPH
medication and the outpatient setting. In that way we believe
that prostatic embolisation may be an alternative to surgery
for treatment of moderately or severe LUTS secondary to
BPH. In fact prostatic embolisation patients had an IPSS
improvement of 62.5 % (from a mean IPSS of 15 before
treatment to 9 at 36 months after PAE). In the same way
Qmax increased 51 % (from 9.2 to 13.9 mL/s after PAE).
Although in this study the improvement of the mean
uroflowmetry obtained by PAE patients is modest when
compared to surgery patients (51 % for PAE and 125 %
for TURP) the IPSS outcome after PAE is comparable to the
one obtained by surgery (IPSS improvement of 62.5 % for
PAE and IPSS improvement of 70.6 % for TURP). Future
studies with longer follow-up will answer the question of
longevity of the PAE outcome.
After PAE there is improvement in IPSS, Qmax and
PVR. After 3 and 6 months there is a deterioration in those
parameters in some patients. It is necessary to study the
patients for longer periods of time in order to evaluate the
durability of the results. Eight patients (3.4 %) followed up
for 36 months showed continued improvement.
This study has some limitations and bias should also be
considered. The variables used in this work are subjective
although IPSS is a validated questionnaire. We only per-
formed one uroflowmetry assessment and at least two would
be helpful to define an average and reduce variability. How-
ever the Qmax improvement is not as important as the IPSS
improvement.
Prostate volume was measured by TRUS and it is always
operator dependent. We tried to reduce bias by having the
same operator measuring volumes in the same patient but
sometimes that was not possible. Nevertheless, with all the
limitations that they might have, they are the same param-
eters used in almost any trial on BPH.
Pressure flow studies were not considered as part of the
clinical evaluation in this trial because of their invasive
nature. As in the majority of other trials, pressure flow
studies were not included for the same reason.
We also tried to minimize some expected bias concerning
the filling of the questionnaires. All patients filled the
questionnaires by themselves without any exterior help
(i.e. they were self-filled by the patients as recommended).
Finally, this is a single-centre non-randomised and non-
comparative study. Although the results are promising more
studies are needed, especially multicentre randomised con-
trolled trials with longer follow-up.
We conclude that PAE in selected BPH patients is a
safe procedure with low morbidity, no sexual dysfunc-
tion, and with good short- and medium-term follow-up
and may be an alternative to surgery in moderately and
severely symptomatic patients.
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